Spots Global Cancer Trial Database for borderline resectable pancreatic adenocarcinoma
Every month we try and update this database with for borderline resectable pancreatic adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | NCT05688215 | Borderline Rese... Locally Advance... | Biospecimen Col... Computed Tomogr... Core Biopsy Fluorouracil Irinotecan Leucovorin Leucovorin Calc... Oxaliplatin Quemliclustat Zimberelimab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma | NCT03704662 | Pancreatic Canc... | Stereotactic Bo... Preoperative Fr... | 18 Years - | Medical College of Wisconsin | |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | NCT04940286 | Borderline Rese... Resectable Panc... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... | Durvalumab Gemcitabine Nab-paclitaxel Oleclumab | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer | NCT04423731 | Locally Advance... Chemotherapy Ef... Borderline Rese... Pancreatectomy | Folfirinox | 18 Years - | Oslo University Hospital | |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | NCT04481204 | Borderline Rese... Locally Advance... Resectable Panc... | Cisplatin Fluorouracil Gemcitabine Irinotecan Leucovorin Nab-paclitaxel Oxaliplatin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | NCT05825066 | Pancreas Adenoc... Borderline Rese... Locally Advance... | Nab paclitaxel Gemcitabine Radiological As... mFOLFIRINOX | 18 Years - | Wake Forest University Health Sciences | |
| Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer | NCT05356039 | Pancreas Cancer Pancreas Neopla... Pancreas Diseas... Pancreas Adenoc... Surgery Chemotherapy Ef... Quality of Life Locally Advance... Borderline Rese... | 18 Years - | Umeå University | ||
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | NCT05546411 | Pancreatic Canc... Resectable Panc... Borderline Rese... Pancreatic Aden... | mFOLFIRINOX 5-Fluorouracil ... Oxaliplatin Irinotecan Leucovorin NIS793 Chemoradiation Surgery | 18 Years - | Dana-Farber Cancer Institute | |
| Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) | NCT04106856 | Borderline Rese... Locally Advance... Locally Advance... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | Hypofractionate... Losartan Losartan Potass... Quality-of-Life... Questionnaire A... | 18 Years - | University of Utah | |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | NCT04481204 | Borderline Rese... Locally Advance... Resectable Panc... | Cisplatin Fluorouracil Gemcitabine Irinotecan Leucovorin Nab-paclitaxel Oxaliplatin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma | NCT03318497 | Pancreatic Aden... | 3'-deoxy-3'-[F-... Computed Tomogr... Positron Emissi... Laboratory Biom... | 18 Years - | University of Texas Southwestern Medical Center | |
| Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer | NCT05356039 | Pancreas Cancer Pancreas Neopla... Pancreas Diseas... Pancreas Adenoc... Surgery Chemotherapy Ef... Quality of Life Locally Advance... Borderline Rese... | 18 Years - | Umeå University | ||
| Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer | NCT05356039 | Pancreas Cancer Pancreas Neopla... Pancreas Diseas... Pancreas Adenoc... Surgery Chemotherapy Ef... Quality of Life Locally Advance... Borderline Rese... | 18 Years - | Umeå University | ||
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer | NCT04669197 | Untreated Resec... Borderline Rese... Locally Advance... | Paclitaxel prot... Gemcitabine Cisplatin Hydroxychloroqu... | 18 Years - | HonorHealth Research Institute | |
| Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma | NCT03704662 | Pancreatic Canc... | Stereotactic Bo... Preoperative Fr... | 18 Years - | Medical College of Wisconsin | |
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | NCT02446093 | Borderline Rese... | Aglatimagene be... Chemoradiation Stereotactic bo... Surgery | 18 Years - | Candel Therapeutics, Inc. | |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | NCT05546411 | Pancreatic Canc... Resectable Panc... Borderline Rese... Pancreatic Aden... | mFOLFIRINOX 5-Fluorouracil ... Oxaliplatin Irinotecan Leucovorin NIS793 Chemoradiation Surgery | 18 Years - | Dana-Farber Cancer Institute | |
| NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | NCT04484909 | Borderline Rese... Locally Advance... Resectable Panc... Stage III Pancr... | Hafnium Oxide-c... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma | NCT05083247 | Pancreatic Neop... Pancreatic Aden... Borderline Rese... | mFOLFIRINOX or ... Isotoxic High-D... Surgery | 18 Years - | Erasme University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
